Clinical Trial Update: A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study of JNJ-77242113 for generalized pustular psoriasis and erythrodermic psoriasis is active but not recruiting, with results posted on 2026-01-28.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythrodermic Psoriasis
• Generalized Pustular Psoriasis

Drugs mentioned

• JNJ-77242113

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-28